AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3878103
Drug: Intravenous lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lignocaine before propofol injection
Trial: 22241354
Drug: Aprepitant (APR)
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant (APR) administered with conventional antiemetic therapy
Trial: 22241354
Drug: Conventional antiemetic
RxNorm normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional antiemetic therapy (serotonin receptor antagonist and dexamethasone)
Trial: 20424852
Drug: Silicone oil
RxNorm normalized name: SILICONE OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone oil suspended with 0.2 mg/ml aspirin (AS SiO)
Trial: 18065575
Drug: 2.8 g
RxNorm normalized name: glycerin 2.8 GM per 2.7 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.8 g alginate-pectin beverage
Trial: 18065575
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g alginate-pectin beverage
Trial: 12399698
Drug: Chlorhexidine (CHX)
RxNorm normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (CHX) varnish treatment after professional tooth cleaning in mothers with high salivary MS counts
Trial: 7594663
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of PRP‐OMP or PRP‐T at 4, 6, and 14 months
Trial: 2124027
Drug: T4 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T4 (0.5 mg daily for 6‐14 days)
Trial: 7004624
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (CMFT)
Trial: 7004624
Drug: Estrogen receptor-positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen receptor-positive tumors (ER+)
Trial: 7004624
Drug: Estrogen receptor-negative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen receptor-negative tumors (ER-)
Trial: 31159856
Drug: Long-term maintenance
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term maintenance antidepressants (citalopram, sertraline, fluoxetine, mirtazapine)
Trial: 19106242
Drug: L-alpha-glycerophosphocholine
RxNorm normalized name: L-alpha-Glycerophosphocholine
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-alpha-glycerophosphocholine
Trial: 17302055
Drug: Xiongshao Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiongshao Capsule (XC)
Trial: 9756169
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone 2 mg/m2 during radiotherapy
Trial: 9756169
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone 4 mg/m2 during radiotherapy
Trial: 8161291
Drug: Low-tryptophan diet
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-tryptophan diet (160 mg/d) followed by a drink of 15 amino acids
Trial: 26423732
Drug: Garlic-containing meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic-containing meal (100 g white bread, 15 g butter, and 5 g raw, crushed garlic)
Trial: 26423732
Drug: Garlic-free control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic-free control meal (100 g white bread and 15 g butter)
Trial: 26423732
Drug: Purified garlic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified garlic extract (0.5 μL/mL) in Mono Mac 6 cells
Trial: 12952518
Drug: Soft tissue
RxNorm normalized name: INSULIN DETEMIR 14.2 mg in 1 mL SOFT TISSUE IMPLANT [Levemir]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft tissue massage (6 treatments)
Trial: 12952518
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment, waiting list)
Trial: 10663354
Drug: Appropriate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate treatment of endometriosis
Trial: 9063757
Drug: Diflunisal (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (500 mg)
Trial: 1648849
Drug: Sodium selenite
RxNorm normalized name: Sodium selenite
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sodium selenite therapy (500 micrograms daily)
Trial: 6356320
Drug: sucralfate, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucralfate, 4 g daily
Trial: 6356320
Drug: cimetidine, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine, 1 g daily
Trial: 25567460
Drug: FSP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSP regimen plus a supplement of 'Parma pap' (Group 2)
Trial: 21873922
Drug: Home-based computer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based computer vergence/accommodative therapy (HBCVAT+)
Trial: 21873922
Drug: Home-based pencil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based pencil push-up therapy (HBPP)
Trial: 20396714
Drug: artrofoon for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: artrofoon for 12 months in addition to basis therapy
Trial: 20396714
Drug: basis therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: basis therapy
Trial: 2927860
Drug: Amnioinfusion with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amnioinfusion with 1000 mL normal saline initially and every 6 hours until delivery
Trial: 26364765
Drug: Bepotastine besilate
RxNorm normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bepotastine besilate (10 mg orally twice daily for 2 weeks)
Trial: 20697755
Drug: Oral home
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral home care (Control)
Trial: 16494704
Drug: Early discharge
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early discharge at > or = 1650 g
Trial: 16494704
Drug: Routine discharge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine discharge at > or = 1800 g
Trial: 12970329
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg daily
Trial: 9370111
Drug: Etomoxir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomoxir (100 mg/day for 3 days)
Trial: 1283591
Drug: Verapamil 240
RxNorm normalized name: verapamil 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 240 mg/day for 14 days
Trial: 1283591
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium intake (11 g/day)
Trial: 1283591
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium intake (4 g/day)
Trial: 4026927
Drug: Sulfadiazine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadiazine (4 mg/kg twice daily, initial dose 8 mg/kg)
Trial: 4026927
Drug: Sulfafurazole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfafurazole (50 mg/kg four times a day)
Trial: 27909165
Drug: High-dose psilocybin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose psilocybin (22 or 30 mg/70 kg)
Trial: 27909165
Drug: Placebo-like dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-like dose (1 or 3 mg/70 kg)
Trial: 25141203
Drug: Papacarie™ gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papacarie™ gel for chemo‐mechanical caries removal
Trial: 21074011
Drug: Continuous LNG
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous LNG 90 mcg/EE 20 mcg
Trial: 19913143
Drug: Cyclic LNG
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic LNG 100 mcg/EE 20 mcg
Trial: 17149671
Drug: Provider-delivered, individualized,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provider-delivered, individualized, stage-based interventions; details on dosage and duration not available.
Trial: 17149671
Drug: Audio-computerized-assisted, self-interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Audio-computerized-assisted, self-interviewing systems; details on dosage and duration not available.
Trial: 12670085
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + MPTS (scaling and root-planing followed by one dose per pocket of minocycline microspheres, 1 mg)
Trial: 8009754
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (2.7 g n‐3 fatty acids per day)
Trial: 8009754
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (4 1‐g capsules per day)
Trial: 2691476
Drug: ticarcillin/clavulanate (3.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ticarcillin/clavulanate (3.1 g every 4 h)
Trial: 2691476
Drug: gentamicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gentamicin plus clindamycin (900 mg every 8 h)
Trial: 1091001
Drug: Colestipol hydrochloride
RxNorm normalized name: Colestipol Hydrochloride
DrugBank: Colestipol (DB00375)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colestipol hydrochloride (5 gm three times daily)
Trial: 25504487
Drug: Education and
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education and daily exercise (4 spinal movements for daily practice)
Trial: 22239052
Drug: Eucalyptol-limonene-pinene enteric
RxNorm normalized name: pinene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eucalyptol-limonene-pinene enteric soft capsule (C group)
Trial: 19845513
Drug: Fixed Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed Atenolol Amlodipine Combination (FAAC) monotherapy
Trial: 19845513
Drug: Fixed Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed Atenolol Amlodipine Combination (FAAC) in combination therapy
Trial: 19845513
Drug: Fixed Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed Atenolol Amlodipine Combination (FAAC)
Trial: 15153724
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of mitoxantrone (6 weekly and 20 fortnightly instillations)
Trial: 15153724
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of mitoxantrone (3 fortnightly and 10 monthly instillations)
Trial: 15153724
Drug: 100 MU
RxNorm normalized name: Tu Mu Xiang
DrugBank: Inula helenium root (DB14350)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 MU of IFNalpha‐2b (8 weekly, 8 fortnightly and 6 monthly instillations)
Trial: 9652560
Drug: rhIGF‐I 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I 40 microg/kg daily
Trial: 9652560
Drug: rhIGF‐I 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I 20 microg/kg daily
Trial: 3317057
Drug: 5-ASA at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ASA at a dosage of 4.8 g per day
Trial: 3317057
Drug: 5-ASA at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ASA at a dosage of 1.6 g per day
Trial: 29797519
Drug: Ustekinumab 90
RxNorm normalized name: ustekinumab 90 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 90 mg every 12 weeks
Trial: 29797519
Drug: Ustekinumab 90
RxNorm normalized name: ustekinumab 90 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 90 mg every 8 weeks
Trial: 29797519
Drug: Prior dose
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior dose adjustment groups
Trial: 10475721
Drug: Olanzapine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (3 mg)
Trial: 9084525
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 3 mg + 10 ml 2% lidocaine before general anesthesia (group II)
Trial: 9084525
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 3 mg + 3 ml 2% lidocaine before wound closure (group III)
Trial: 9084525
Drug: Non-steroid analgesics
RxNorm normalized name: NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroid analgesics (diclofenac sodium 50 mg, iv, q4h) (group I)
Trial: 2017271
Drug: Intravenous L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-carnitine therapy (2 g i.v. 3 times weekly for 6 months)
Trial: 2017271
Drug: Intravenous L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-carnitine therapy (1 g i.v. for 10 months after initial treatment)
Trial: 2017271
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 g i.v. 3 times weekly for 6 months)
Trial: 2017271
Drug: Intravenous L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-carnitine therapy
Trial: 6218109
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of mezlocillin (1 g every eight hours)
Trial: 6218109
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of mezlocillin (2 g every eight hours)
Trial: 6218109
Drug: Both routes
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both routes of administration (i.m. and i.v.)
Trial: 6218109
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of mezlocillin
Trial: 26137956
Drug: AZD3241 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3241 600 mg orally twice a day for 8 weeks
Trial: 22292526
Drug: i.v. alteplase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. alteplase (rt-PA) at a dosage of 0.9 mg/kg of body weight
Trial: 22292526
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment according to national guidelines
Trial: 17584058
Drug: Tumor necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor necrosis factor-alpha monoclonal antibodies
Trial: 15020186
Drug: SMS reminders
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS reminders for vaccination doses
Trial: 10479167
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with low-dose IFN-alpha
Trial: 1820675
Drug: Tenoxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam (20 mg intramuscular)
Trial: 6293073
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy with tamoxifen and drostanolone propionate (n = 34)
Trial: 6293073
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with the CMF protocol (n = 30)
Trial: 6293073
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hormonal therapy and chemotherapy (n = 34)
Trial: 31587960
Drug: Bruder Compress
RxNorm normalized name: Ulva compressa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bruder Compress twice a day
Trial: 31587960
Drug: Warm washcloth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm washcloth used for ten minutes twice a day without reheating
Trial: 31587960
Drug: Bruder Compress
RxNorm normalized name: Ulva compressa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bruder Compress twice daily vs once daily
Trial: 21343342
Drug: A0001 (α-tocopherylquinone)
RxNorm normalized name: Tocopherylquinone
DrugBank: Tocopherylquinone (DB14094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A0001 (α-tocopherylquinone) at doses of 0.25 g and 0.5 g under fasted state; 0.5 g to 6 g with high-fat meal
Trial: 21343342
Drug: A0001 (α-tocopherylquinone)
RxNorm normalized name: Tocopherylquinone
DrugBank: Tocopherylquinone (DB14094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A0001 (α-tocopherylquinone) administered in divided doses (0.735 g, 3 times per day)
Trial: 17378175
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody A33 in Phase I trial
Trial: 17378175
Drug: Combination chemotherapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapies in Phase II trial
Trial: 17378175
Drug: New therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New therapy using newly developed material in Phase III trial
Trial: 17378175
Drug: Antihypertension agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertension agents in Phase III trial
Trial: 11867968
Drug: minocycline 100/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: minocycline 100/50 mg
Trial: 11867968
Drug: lymecycline 300
RxNorm normalized name: lymecycline 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lymecycline 300 mg
Trial: 11867968
Drug: minocycline 50
RxNorm normalized name: minocycline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: minocycline 50 mg
Trial: 9865617
Drug: Acetazolamide (AZM)
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide (AZM) 500 mg/day for 2 weeks
Trial: 24523666
Drug: Lower intensity
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower intensity renal replacement therapy (RRT)
Trial: 24523666
Drug: Higher intensity
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher intensity renal replacement therapy (RRT)
Trial: 19723080
Drug: Grape Juice
RxNorm normalized name: grape juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape Juice (5.5 mL/kg daily for 8 weeks)
Trial: 16951956
Drug: Radiosynoviorthesis (RSO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiosynoviorthesis (RSO) with intra‐articular radionuclide plus glucocorticoid (GC) injection
Trial: 16951956
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus glucocorticoid (GC) injection
Trial: 11559545
Drug: ICI 182,780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 182,780 50 mg
Trial: 11559545
Drug: ICI 182,780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 182,780 125 mg
Trial: 11559545
Drug: ICI 182,780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 182,780 250 mg
Trial: 9786257
Drug: Conventional long-term
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional long-term anticoagulation (LTA) therapy: initial intravenous standard heparin followed by warfarin on days 3 to 5, continued for 3 months.
Trial: 9786257
Drug: Short-term anticoagulation
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term anticoagulation therapy: same heparin therapy followed by warfarin on days 2 to 3, continued for 6 weeks.
Trial: 9786257
Drug: Short-term anticoagulation
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term anticoagulation therapy
Trial: 9786257
Drug: Conventional long-term
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional long-term anticoagulation (LTA) therapy
Trial: 8152348
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (PUFA) 20 g
Trial: 8152348
Drug: n-6 PUFA
RxNorm normalized name: 18:3 (n-6)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-6 PUFA 20 g
Trial: 2463524
Drug: Pacemaker implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacemaker implant (VVI or DDD)
Trial: 1711873
Drug: Low-dose prednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prednisolone
Trial: 28836493
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus an enhanced rehabilitation package (patient-held information workbook, goal-setting diary, six additional therapy sessions)
Trial: 24165282
Drug: Intrathecal baclofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal baclofen treatment for three months
Trial: 24165282
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for three months